UNITED STATES SECURITIES EXCHANGE COMMISSION
                         WASHINGTON, D.C.  20549

                              FORM 10-KSB

[X] ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
    EXCHANGE ACT OF 1934

                       FOR FISCAL YEAR ENDED:  September 30, 2003

                       COMMISSION FILE NO.:   000-49955

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
    EXCHANGE ACT OF 1934

                       FOR THE TRANSITION PERIOD FROM _____ TO _____

                         CIMBIX  CORPORATION
          -------------------------------------------------
           (Name of small business issuer in its charter)

            Washington                            91-2060082
-----------------------------------    -----------------------------
(State or other jurisdiction of              (I.R.S. Employer
 incorporation or organization)               Identification No.)

#1710, 1000 2nd Avenue
Seattle, Washington                               98104
-----------------------------------------    -----------------------
(Address of principle executive offices)        ( Zip Code)

Issuer's telephone number:  (206) 973-1895
                            -----------------------

Former Name and Address:

         Corporate Development & Innovation, Inc.
         4911 Cabot Drive, Richmond, BC Canada  V7C 4J5

Securities registered under Section 12(b) of the Exchange Act:  None
Securities registered under Section 12(g) of the Exchange Act:

         Common Stock, $0.0001 par value
         ------------------------------------
          (Title of Class)

Check whether the issuer (1) filed all reports required to be filed
By Section 13 or 15(d) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days.            YES [x]    NO [ ]

Check if disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will
be contained, to the best of registrant's knowledge, in definitive
proxy or information statements incorporated by reference in Part III
of this Form 10-KSB or any amendment to this Form 10-KSB.   [ ]

Issuer's revenues for its most recent fiscal year was $9,500

The aggregate market value of the voting common stock held by non-
affiliates of the Registrant as of September 30, 2003 is NIL dollars,
based on the fact that there is no public market for the registrants
common stock.

State the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date:

12,717,100 SHARES OF $0.0001 PAR VALUE COMMON STOCK OUTSTANDING AS OF
SEPTEMBER 30, 2003.

Transitional Small Business Disclosure Format (check one):
                                                    Yes [ ] No [ x ]

<PAGE>

PART 1

Certain statements contained in this Form 10-KSB constitute "forward-
looking statements" within the meaning of Section 27A of the
Securities Act of 1933,as amended (the "Securities Act"), and Section
21E of the Exchange Act. These statements, identified by words such
as "plan", "anticipate," "believe," "estimate," "should," "expect"
and similar expressions, include our expectations and objectives
regarding our future financial position, operating results and
business strategy. These statements reflect the current views of
management with respect to future events and are subject to risks,
uncertainties and other factors that may cause our actual results,
performance or achievements, or industry results, to be materially
different from those described in the forward-looking statements.
Such risks and uncertainties include those set forth under the
captions "Description of Business", "Management's Discussion and
Analysis or Plan of Operation" and elsewhere in this Form 10-KSB. We
do not intend to update the forward-looking information to reflect
actual results or changes in the factors affecting such forward-
looking information.

ITEM 1.  DESCRIPTION OF BUSINESS

GENERAL

The Company was incorporated under the laws of the State of
Washington on August 17, 2000 and has been a reporting issuer with
the United States Securities and Exchange Commission since November
2000.  On August 26, 2003, the Company changed its name from
Corporate Development and Innovation, Inc. to Cimbix Corporation
("Cimbix", the "Company").

The Company's business is still in its early developmental and
promotional stages and to date, the Company's primary activities
have involved significant re-structuring and re-organization;
completion of a private placement; and the execution of a share
exchange agreement with a privately held Nevada corporation named
Milliennium Business Group USA, Inc. ("MBG USA").

Since the Company's inception and up until approximately March of
2003, the Company was engaged solely in the market development and
sale of vitamins, minerals, nutritional supplements, and other health
and fitness products over the internet.  The Company's limited focus
was the result of an exclusive license agreement with
Vitamineralherb.com to market, distribute and sell their
Vitamineralherb.com products to health and fitness professionals in
the state of Illinois less the counties of Jo Davies, Stevenson,
Winnebago, Rock Island, Henry, Will, Kankakee, Iroquois and
Vermillion.  The three year license agreement with
Vitamineralherb.com expired and the Company made no plans to renew.
Instead, the Company's continued interest in this market sector has
been re-focused on the development, manufacture and marketing of a
unique, but much broader and more encompassing line of custom blended
vitamins, minerals and herbs now being carried out through the
Company's newly formed Consumer Products division called "Vitacore
Nutraceuticals".

In early September 2003, the Company's new Vitacore division was also
introduced to a unique patented line of oral dosed vitamin and
mineral spray products called "micro sprays" manufactured by a U.S.
company called Micro Laboratories.  These micro spray products are
unique because they are not only capable of delivering smaller
concentrations of certain nutritional supplements quicker and more
efficiently by spraying them under the tongue, but they also contain
no alcohol, preservatives or natural sugars.  Instead, they contain a
naturally derived sugar substitute called "xylitol", which makes
these micro sprays "diabetic-safe".  We are currently trying to
finalize discussions with Micro Laboratories over possible
distribution and marketing arrangements within key market niches and
key territories and sectors of Canada as well as foreign health care
industry.

On March 24, 2003, the Company acquired 100% of the shares of MBG USA
making it a wholly owned subsidiary.  Our plan is to compliment,
augment and extend the early stage activities and business plans of
the Company.

As a result of these new business initiatives and activities the
Company has been able to undertake the development and the creation
of the following three additional business segments, in addition to
its new Vitacore division. These four new active business divisions
are as follows:

1. Consumers Products Division

The Consumer Products Division provides a range of clinically proven,
highly proprietary, unique and effective vitamin, mineral and herb
products and technologies for sale through a combination of wholesale
distributors and internet based sales and marketing efforts. These
products are in the process of being branded under the name "VitaCore
Nutraceuticals" using the registered domain name of www.vitacore.com.
A complete list of these products can be found at our website.
The Vitacore products have been formulated by master herbalists Dr.
David Chuah and Mr. Victor Shim, under the terms and conditions of a
contract manufacturing relationship using a proprietary combination
of western Aboriginal medicine, homeopathic techniques and
traditional Chinese medicine {"TCM"} practices. The result is a line
of premium value added products with extreme potency, refined by
years and years of clinical practice and expertise. Currently, the
Vitacore team is preparing final label designs and marketing
literature and hopes to be able to commercialize its various products
in the new year.

The Company is also presently developing various direct advertising
and internet based marketing initiatives through pre-existing
distribution channels to promote the value added features and
benefits of its uniquely formulated nutraceutical and botanical
extract products.  Marketing efforts shall be supported by live
attendants, order fulfillment centers and a business-to-consumer
platform both of which Vitacore and Cimbix plan on utilizing to help
establish themselves as market leaders within certain specialty
markets of the nutraceutical and botanical supply industry.
One of our new business initiatives is the exclusive distribution and
supply agreement that we have entered with NITA HealthWEB Inc.
("NITA"). NITA provides procurement and fulfillment of medical
supplies, EMS equipment and related products to remote Aboriginal
healthcare centers.  These remote healthcare centers service
predominately Aboriginal people amongst which, the incidence of
diabetes and related ailments such as arthritis and retinopathy have
reached pandemic proportions. The aim of the Vitacore supplement
program is to allow greater flexibility and choice in determining how
to best treat health problems and to provide products that are
similar to traditional holistic preventative medicine practices.
In addition, the Company's Vitacore division has also acquired
certain non-exclusive marketing and sales rights to a line of
proprietary enzyme based products manufactured by a company called
SIPCO Industries Ltd. SIPCO is an ISO 9002 registered manufacturer
which produces a naturally fermented bio-enzymatic root 'soak'
product called "Garden Utopia". Garden Utopia is manufactured by a
Canadian company called SIPCO Industries Ltd., and has been found to
help stimulate significant increased growth and maturation of various
plants, shrubs, flowers and a diverse range of vegetation and crops.
The Garden Utopia product has been reviewed and granted status as an
Organic Crop Production Aid by a U.S. not-for-profit organization
called "O.M.R.I." (the Organic Materials Research Institute) in
Oregon, USA.  Our plan is to perform further testing and evaluations
as they relate to the production of the various vitamins, minerals
and herbs and the possible commercial re-sale of this Garden Utopia
product through established distribution networks.

2. Healthcare Division

With the help of an affiliate company called CIBRON Corporation, the
Company's healthcare division acts as a sales and marketing
representative or "manufacturers agent" for a number of medical
device manufacturing companies, related healthcare distribution
entities, as well as the healthcare related products  and services of
one U.S. publicly traded company named Alternet Systems, Inc.  As a
manufacture's agent, the Company's healthcare division provides a
fully integrated series of programs including sales training,
detailing, in-servicing and after market sales support, all of which
are designed to help distributors increase their inventory turnovers
and to sell more products. A complete list of these products can be
found on our website.

3. Consultancy Services Division

The Company's newly formed consultancy service division aims to
provide consultancy and brokerage services to various clients in the
wireless internet communication and healthcare industry who, in turn,
provide communication services to remote Aboriginal communities and
their healthcare centers.   As the direct result of a strategic
alliance with an affiliate company named CIBRON Corporation, the
Company is an authorized agent to all five (5) of the following
information technology and internet communications companies:

A. Softhill Technologies Ltd. ["Softhill"] utilizes an 802.11b
wireless [Wi-Fi] system with unique Network Operating Systems
["N.O.S."] and Network Management Systems ["N.M.S."] software
called 'Brilan' which is used to bridge multiple L.A.N.'s and
create mobile W.A.N's. (www.softhill.com for more information)

B. Astriix Wireless Solutions, Inc. ["Astriix"] utilizes a
combination of proprietary technologies to deploy a fully
meshed, plug and play, Wi-Fi network that enables users to roam
across an extended wireless network footprint the first of its
kind in Canada and one of the first in the world. Astriix
proprietary Wi-Fi network enables users to access high bandwidth
applications like video-conferencing and voice over internet
protocol while staying connected over an extended coverage area.
The net result is a superior broadband wireless distributed wide
area network that can dramatically improve the speed, efficiency
and range of web enabled services so they may be used by any
number of end-users sharing and or accessing this virtual
private communications network. (www.astriix.com for more
information)

C. Alternet Systems Ltd. ["Alternet"] an NASDAQ OTC:BB reporting
issuer [ticker symbol "ASYI"] owns and operates a highly
proprietary satellite driven, web-enabled caching broadcast
server technology and an impressive suite of software products
and services, which in collaboration with Radian Technologies,
Hewlett Packard Canada and INFOSat Telecommunications
Inc., provides geographically remote communities with a vast
array of high speed internet based services. One such service
[already commercialized] is called "1NterLink" which is an
educational service module designed specifically for Indigenous
Aboriginal communities and which utilizes Alternet's hardware
and software technology exclusively. (www.alternetsystems.com
for more information)

D. Claremont Technologies Corp. ["Claremont"] an NASDAQ OTC:BB
reporting issuer [ticker symbol "CTTG"] is a wireless internet
communications company with three (3) primary focuses; i) the
establishment of 802.11b wireless WI-Fi VPN networks ii) the
sale and promotion of MOBIUS disposable cellular phones within
the vertical consumer marketplace defined as 'retail electronic
stores' and iii) the sale and promotion of safe cell tab devices
for neutralizing the harmful effects of EM radiation found in
and around the above two market niches. (www.claremont-
technologies.com for more information)

E. NITA HealthWEB Inc., ["NITA"] provides a nationally consolidated
program allowing hundreds of Canadian remote Aboriginal
healthcare centers to purchase a comprehensive offering of
consumer medical supplies and equipment at substantial cost
savings. NITA HealthWEB's web-enabled consolidated healthcare
purchasing program ensures both significant time and cost
savings for its Aboriginal HCC customers.
(www.nitahealthweb.com for more information)

It is important to note that many of the above services were
developed out of the Company's desire to help service the broader
needs of some of the more northern remote, healthcare clients and
communities. Many of these services were essentially required as part
of a viable, cost effective "last mile solution" in order to bring
hi-speed digital internet communications to remote areas and
communities. Without broadband service, the ability to effectively
procure and fulfill medical supplies was and still is very limited.

The revenue model for the Company's Consultancy Services Division is
to simply facilitate business on behalf of its clients as either a
consultant or a broker in order to generate revenue based and future
business opportunities which can be invoiced to the client on as a
percentage of the business it generates.  Since these initiatives
have only recently been developed, thus far, they have not generated
any revenues or sales for the Company.  However, beginning in the new
year, the Company anticipates that this will change.

4. Intellectual Property and Technology Transfer Division

The wholly owned subsidiary of the Company, MBG USA, forms the
Company's intellectual property and technology transfer division.
With a strong intellectual property position based on four validly
issued and assigned U.S. Patents [all in the area of dental implant
abutment components, devices and techniques] it is the Company's
intention over the next several months, to develop and implement a
legal defense strategy to help extract financial compensation from
certain entities which have chosen to willfully infringe on the
Company's patents by commercializing similar technologies, further to
which the MBG USA entity has already been able to effectuate and
finalize a U.S. court directed legal settlement with one infringing
company (dated and executed on June 26, 2002) which resulted in a
fully paid up license fee and cash settlement of $280,000 USD.
Management plans to further evaluate, develop, manage and fund the
commercialization, sub-license and or commercial sale of these
various assets.  The Company hopes to be a position to establish more
cost effective and differentiated business solutions for its various
products and services. Our ability to continue with the business plan
is contingent upon our obtaining additional capital to assist in
developing the concept and the new operational plan.

DEVELOPMENTS AND CONTEMPLATED ACTIVITIES

We currently have minimal cash reserves and a significant working
capital deficit.   Accordingly, our ability to pursue our plan of
operations is contingent on our being able to obtain funding for the
development and commercialization of our products and services.  We
plan to commence an offering in the form of equity financing from the
sale of our common stock in the principal amount of up to $350,000 to
persons who are "accredited investors" in private placement
transactions.  There is no assurance we will be able to raise any
funds through this offering.

The Company recently filed the required forms with NASDAQ to seek a
quotation on the OTC Bulletin Board. If approved, the Company will
incur regulatory compliance costs to maintain our trading status.
The amount of these costs is not known at this time.

SUBSIDIARIES

We entered into a share exchange agreement with the shareholders of
MBG USA.  The acquisition of MBG USA makes it a wholly owned
subsidiary of the Company.  With the acquisition of MBG USA, the
Company can further evaluate, develop, manage, fund and exploit the
commercialization, sub-license and commercial sale of these assets.

PATENTS AND TRADEMARKS

We do not own any patent or trademark legally.  However, we do
currently own the internet domain www.cimbix.com and www.vitacore.com.
Through our wholly owned subsidiary, MBG USA, the Company also
beneficially owns four U.S. validly issued patents.  These patents
are all in the area of dental implant abutment components, devices
and techniques.  The patents are identified as number 5,527,182,
5,873,721, 6,126445 and 6,283,753.  Our Intellectual Property and
Technology Transfer division is currently developing a legal defence
strategy to protect, maintain and help extract financial compensation
from certain entities which may have chosen to 'wilfully' infringe on
these patents by commercializing similar technologies.

RESEARCH AND DEVELOPMENT EXPENDITURES

The Company expended no further monies on research and development
associated with Vitamineralherb.com.  In fact, the three year
Vitamineralherb.com license which was granted by Mr. Edwin Lao to the
Company in return for which the Company issued a total of 7,500,000
shares of its common stock to Mr. Lao, has since expired and the
Company decided not to renew.

The Company has also entered into a share exchange agreement with MBG
USA issuing a total of 4,018,000 shares of its common stock, 500,000
shares of its preferred stock and 1,938,000 warrants so that MBG USA
becomes a wholly owned subsidiary of the Company.  Each share of the
preferred stock issued to the shareholders of MBG USA, is also
convertible into two shares of common stock of the Company. Other
than the share issuance, the Company have not expended any money on
research and development associated with MBG USA except for costs
relating to the development, creation and maintenance of the new
corporate websites of Vitacore and Cimbix.  The Company incurred
$5,750 in consulting fees to date. The Company is also building an e-
commerce engine for its Vitacore site.  This process is not yet
complete and is ongoing. The Company anticipates that costs will not
be more than $7,500 and expects ongoing maintenance and support costs
to be approximately $500 per month.

COMPETITION

The electronic commerce industry is new, rapidly evolving and
intensely competitive, and Cimbix expects competition to intensify in
the future. Barriers to entry are minimal and current and new
competitors can launch sites at a relatively low cost. In addition,
the vitamin, supplement, mineral and alternative health product
market is very competitive and highly fragmented, with no clear
dominant leader and increasing public and commercial attention.

The Company's competitors can be divided into several groups
including:

- traditional vitamins, supplements, minerals and alternative health
products retailers;
- the online retail initiatives of several traditional vitamins,
supplements, minerals and alternative health products retailers;
- online retailers of pharmaceutical and other health-related
products that also carry vitamins, supplements, minerals and
alternative health products;
- independent online retailers specializing in vitamins, supplements,
minerals and alternative health products;
- mail-order and catalog retailers of vitamins, supplements, minerals
and alternative health products, some of which have already developed
online retail outlets; and
- direct sales organizations, retail drugstore chains, health food
store merchants, mass market retail chains and various
manufacturers of alternative health products.

Many of the Company's potential competitors have longer operating
histories, larger customer or user bases, greater brand recognition
and significantly greater financial, marketing and other resources
than Cimbix has. In addition, an online retailer may be acquired by,
Receive investments from, or enter into other commercial
relationships with, larger, well-established and well-financed
companies as use of the Internet and other electronic services
increases. Competitors have and may continue to adopt aggressive
pricing or inventory availability policies and devote substantially
more resources to website and systems development than the Company
does. Increased competition may result in reduced operating margins
and loss of market share.

The Company believes that the principal competitive factors in its
market are:

- ability to attract and retain customers;
- breadth of product selection;
- product pricing;
- ability to customize products and labeling;
- quality and responsiveness of customer service

The Company believes that it can compete favorably on these factors.
However, the Company will have no control over how successful its
competitors are in addressing these factors. In addition, with little
difficulty, the Company's online competitors can duplicate many of
the products or services offered on the Company's website.

The Company believes that traditional retailers of vitamins,
supplements, minerals and other alternative health products face
several challenges in succeeding:
-	Lack of convenience and personalized service. Traditional
retailers have limited store hours and locations. Traditional
retailers are also unable to provide consumers with product advice
tailored to their particular situation.
-	Limited product assortment. The capital and real estate intensive
nature of store-based retailers limit the product selection that
can be - economically offered in each store location.
- Lack of Customer Loyalty. Although the larger traditional retailers
often attract customers, many of these customers are only one-time
users. People are often attracted to the name brands, but find the
products too expensive. It is understood that these are quality
products and have value, but the multilevel structure of marketing
often employed by large retailers mandate high prices.

As a result of the foregoing limitations, the Company believes there
is significant unmet demand for an alternative shopping channel that
can provide consumers of vitamins, supplements, minerals and other
alternative health products with a broad array of products and a
convenient and private shopping experience.

Cimbix hopes to attract and retain consumers through the following
key attributes of its business:

- Broad Expandable Product Assortment. The Company's product
selection is substantially larger than that offered by store-based
retailers.
- Low Product Prices. Product prices can be kept low due to volume
purchases through the Company's affiliation with Vitacore and other
licensees. Product prices will also be lower due to Cimbix's lack of
need of inventory and warehouse space. All products are shipped from
the supplier's inventory.
- Accessibility to Customized Products. At minimal cost, health and
fitness practitioners may offer their customers customized products.
- Access to Personalized Programs. Health or fitness professional can
tailor vitamin and dietary supplement regimes to their clients.

REGULATORY ENVIRONMENT

The manufacturing, processing, formulating, packaging, labeling and
advertising of the products that Cimbix sells may be subject to
regulation by one or more U.S. federal agencies, including the Food
and Drug Administration, the Federal Trade Commission, the United
States Department of Agriculture and the Environmental Protection
Agency. These activities also may be regulated by various agencies of
the states, localities and foreign countries in which consumers
reside. The Food and Drug Administration, in particular, regulates
the formulation, manufacture, labeling and distribution of foods,
including dietary supplements, cosmetics and over-the- counter or
homeopathic drugs. Under the Federal Food, Drug, and Cosmetic Act,
the Food and Drug Administration may undertake enforcement actions
against companies marketing unapproved drugs, or "adulterated" or
"misbranded" products. The remedies available to the Food and Drug
Administration include: criminal prosecution; an injunction to stop
the sale of a company's products; seizure of products; adverse
publicity; and "voluntary" recalls and labeling changes. Food and
Drug Administration regulations require that certain informational
labeling be presented in a prescribed manner on all foods, drugs,
dietary supplements and cosmetics. Specifically, the Food, Drug, and
Cosmetic Act requires that food, including dietary supplements, drugs
and cosmetics, not be "misbranded." A product may be deemed an
unapproved drug and "misbranded" if it bears improper claims or
improper labeling. The Food and Drug Administration has indicated
that promotional statements made about dietary supplements on a
company's website may constitute "labeling" for purposes of
compliance with the provisions of the Food, Drug, and Cosmetic Act. A
manufacturer or distributor of dietary supplements must notify the
Food and Drug Administration when it markets a product with labeling
claims that the product has an effect on the structure or function of
the body. Noncompliance with the Food, Drug, and Cosmetic Act, and
recently enacted amendments to that Act discussed below, could result
in enforcement action by the Food and Drug Administration.

The Food, Drug, and Cosmetic Act has been amended several times with
respect to dietary supplements, most recently by the Nutrition
Labeling and Education Act of 1990 and the Dietary Supplement Health
and Education Act of 1994. The Dietary Supplement Health and
Education Act created a new statutory framework governing the
definition, regulation and labeling of dietary supplements. With
respect to definition, the Dietary Supplement Health and Education
Act created a new class of dietary supplements, consisting of
vitamins, minerals, herbs, amino acids and other dietary substances
for human use to supplement the diet, as well as concentrates,
metabolites, extracts or combinations of such dietary ingredients.
Generally, under the Dietary Supplement Health and Education Act,
dietary ingredients that were on the market before October 15, 1994
may be sold without Food and Drug Administration pre-approval and
without notifying the Food and Drug Administration. In contrast, a
new dietary ingredient, i.e., one not on the market before October
15, 1994, requires proof that it has been used as an article of food
without being chemically altered or evidence of a history of use or
other evidence of safety establishing that it is reasonably expected
to be safe. Retailers, in addition to dietary supplement
manufacturers, are responsible for ensuring that the products they
market for sale comply with these regulations. Noncompliance could
result in enforcement action by the Food and Drug Administration, an
injunction prohibiting the sale of products deemed to be
noncompliant, the seizure of such products and criminal prosecution.
The Food and Drug Administration has indicated that claims or
statements made on a company's website about dietary supplements may
constitute "labeling" and thus be subject to regulation by the Food
and Drug Administration. With respect to labeling, the Dietary
Supplement Health and Education Act amends, for dietary supplements,
the Nutrition Labeling and Education Act by providing that
"statements of nutritional support," also referred to as
"structure/function claims," may be used in dietary supplement
labeling without Food and Drug Administration pre-approval, provided
certain requirements are met. These statements may describe how
particular dietary ingredients affect the structure or function of
the body, or the mechanism of action by which a dietary ingredient
may affect body structure or function, but may not state a drug
claim, i.e., a claim that a dietary supplement will diagnose,
mitigate, treat, cure or prevent a disease. A company making a
"statement of nutritional support" must possess substantiating
evidence for the statement, disclose on the label that the Food and
Drug Administration has not reviewed the statement and that the
product is not intended for use for a disease and notify the Food and
Drug Administration of the statement within 30 days after its initial
use. It is possible that the statements presented in connection with
product descriptions on the Company's site may be determined by the
Food and Drug Administration to be drug claims rather than acceptable
statements of nutritional support. In addition, some of the Company's
suppliers may incorporate objectionable statements directly in their
product names or on their products' labels, or otherwise fail to
comply with applicable manufacturing, labeling and registration
requirements for over-the-counter or homeopathic drugs or dietary
supplements. As a result, Vitamineralherb.com may have to remove
objectionable statements or products from its site or modify these
statements, or product names or labels, in order to comply with Food
and Drug Administration regulations. Such changes could interfere
with Cimbix's marketing of products and could cause us to incur
significant additional expenses.

In addition, the Dietary Supplement Health and Education Act allows
the dissemination of "third party literature" in connection with the
sale of dietary supplements to consumers at retail if the publication
meets statutory requirements. Under the Dietary Supplement Health and
Education Act, "third party literature" may be distributed if, among
other things, it is not false or misleading, no particular
manufacturer or brand of dietary supplement is promoted, a balanced
view of available scientific information on the subject matter is
presented and there is physical separation from dietary supplements
in stores. The extent to which this provision may be used by online
retailers is not yet clear, and Cimbix cannot assure you that all
pieces of "third party literature" that may be disseminated in
connection with the products Cimbix offers for sale will be
determined to be lawful by the Food and Drug Administration. Any such
failure could render the involved product an unapproved drug or a
"misbranded" product, potentially subjecting us to enforcement action
by the Food and Drug Administration, and could require the removal of
the noncompliant literature from Cimbix's website or the modification
of Cimbix's selling methods, interfering with Corporate Development
and Innovation continued marketing of that product and causing us to
incur significant additional expenses. Given the fact that the
Dietary Supplement Health and Education Act was enacted only five
years ago, the Food and Drug Administration's regulatory policy and
enforcement positions on certain aspects of the new law are still
evolving. Moreover, ongoing and future litigation between dietary
supplement companies and the Food and Drug Administration will likely
further refine the legal interpretations of the Dietary Supplement
Health and Education Act. As a result, the regulatory status of
certain types of dietary supplement products, as well as the nature
and extent of permissible claims will remain unclear for the
foreseeable future. Two areas in particular that pose potential
regulatory risk are the limits on claims implying some benefit or
relationship with a disease or related condition and the application
of the physical separation requirement for "third party literature"
as applied to Internet sales.

In addition to the regulatory scheme under the Food, Drug and
Cosmetic Act, the advertising and promotion of dietary supplements,
foods, over-the-counter drugs and cosmetics is subject to scrutiny by
the Federal Trade Commission. The Federal Trade Commission Act
prohibits "unfair or deceptive" advertising or marketing practices,
and the Federal Trade Commission has pursued numerous food and
dietary supplement manufacturers and retailers for deceptive
advertising or failure to substantiate promotional claims, including,
in many instances, claims made via the Internet. The Federal Trade
Commission has the power to seek administrative or judicial relief
prohibiting a wide variety of claims, to enjoin future advertising,
to seek redress or restitution payments and to seek a consent order
and seek monetary penalties for the violation of a consent order. In
general, existing laws and regulations apply fully to transactions
and other activity on the Internet. The Federal Trade Commission is
in the process of reviewing its policies regarding the applicability
of its rules and its consumer protection guides to the Internet and
other electronic media. The Federal Trade Commission has already
undertaken a new monitoring and enforcement initiative "Operation
Cure-All," targeting allegedly bogus health claims for products and
treatments offered for sale on the Internet. Many states impose their
own labeling or safety requirements that differ from or add to
existing federal requirements.

The Company cannot predict the nature of any future U.S. laws,
regulations, interpretations or applications, nor can it determine
what effect additional governmental regulations or administrative
orders, when and if promulgated, would have on its business in the
future. Although the regulation of dietary supplements is less
restrictive than that of drugs and food additives, the Company cannot
assure you that the current statutory scheme and regulations
applicable to dietary supplements will remain less restrictive.
Further, Cimbix cannot assure you that, under existing laws and
regulations, or if more stringent statutes are enacted, regulations
are promulgated or enforcement policies are adopted, it is or will be
in compliance with these existing or new statutes, regulations or
enforcement policies without incurring material expenses or adjusting
its business strategy. Any laws, regulations, enforcement policies,
interpretations or applications applicable to Cimbix's business could
require the reformulation of certain products to meet new standards,
the recall or discontinuance of certain products not capable of
reformulation, additional record keeping, expanded documentation of
the properties of certain products, expanded or different labeling or
scientific substantiation.

REGULATION OF THE INTERNET

In general, existing laws and regulations apply to transactions and
other activity on the Internet; however, the precise applicability of
these laws and regulations to the Internet is sometimes uncertain.
The vast majority of such laws were adopted prior to the advent of
the Internet and, as a result, do not contemplate or address the
unique issues of the Internet or electronic commerce. Nevertheless,
numerous federal and state government agencies have already
demonstrated significant activity in promoting consumer protection
and enforcing other regulatory and disclosure statutes on the
Internet. Additionally, due to the increasing use of the Internet as
a medium for commerce and communication, it is possible that new laws
and regulations may be enacted with respect to the Internet and
electronic commerce covering issues such as user privacy, freedom of
expression, advertising, pricing, content and quality of products and
services, taxation, intellectual property rights and information
security. The adoption of such laws or regulations and the
applicability of existing laws and regulations to the Internet may
impair the growth of Internet use and result in a decline in the
Company's sales.

A number of legislative proposals have been made at the federal,
state and local level, and by foreign governments, that would impose
additional taxes on the sale of goods and services over the Internet,
and certain states have taken measures to tax Internet-related
activities. Although Congress recently placed a three-year moratorium
on new state and local taxes on Internet access or on discriminatory
taxes on electronic commerce, existing state or local laws were
expressly excepted from this moratorium. Further, once this
moratorium is lifted, some type of federal and/or state taxes may be
imposed upon Internet commerce. Such legislation or other attempts at
regulating commerce over the Internet may substantially impair the
growth of commerce on the Internet and, as a result, adversely affect
the Company's opportunity to derive financial benefit from such
activities.

EMPLOYEES

Cimbix is a development stage company which currently has a total of
ten (10) individuals who work for and represent the companies various
business interests.  The Company is currently managed by Dr. Andrew
JM Willoughby, who acts as the Company's Chief Executive Officer and
Chairman. Including Dr Willoughby there are a total of three (3) persons
who are considered as employees of the company.  Effective October 1,
2003 these three employees will be compensated annually for their
services utilizing a combination of accrued monthly salary and stock
issuances.These three individuals include; Andrew Willoughby - Chairman
and CEO, Doug Johnson - President & Director and Robert Rosner - VP
Regulatory Affairs and Compliance.  As of the fiscal year ending
September 30,2003, Dr Willoughby was the only indivdual to recieve any
form of a salary draw [$4500.00 in total].

With the exception of Ms. Maribel Jordan who acts as the Company's
general office administrator, the remaining six individuals hold senior
management positions with the company.  These indivudals include, Mr.
Dickson Wong - Chief Financial Officer; Mr. Marlon A Shangi- Chief
Technology Officer; Mr. Donald Walker - Vice President of Channel
Marketing and Licensing;, Mr. David G Roberts- Director of Corporate
Communications; Mr. David J Willoughby-, Vice President of Sales in
Americas and Europe., and Dr. David Chuah- Vice President of Research
and Development in our Vitacore division.  As of September 30, 2003 none
of these individuals had been compensated by the Company for their time
or efforts.  Starting October 1, 2003 however, the efforts of these
six individuals plus those of Ms. Jordan will be compensated thru the
issuance of various stock issuances.

Upon successful financing, the Company will seek to compensate the above
indivduals with some sort of reasonable and insutry standard salay base
or draw against commission as well as hire additional sales and
marketing staff to fulfill its business model.

Several of the above individuals also function in a similar capacity
within MBG USA. Dr. Andrew Willoughby is the President; Mr. Robert
Rosner is the Vice President of Investor Relations and Business
Development, and Corporate Secretary; and Mr. Donald Walker is the
Treasurer.  In February 2003, MBG USA employed both Mr. Douglas
Johnson as sales representative and Mr. David Roberts as an
independent sales consultant to help represent some of the Company's
newly anticipated product offerings.  as of September 30, 2003 both
Mr.Roberts and Mr.Johnson were 100% commissioned sales representatives
who had not yet transacted or completed any sales but had both been
instrumental in helping develop current and precise competitive market
analysis and sourcing new manufactuing client and products for the
Company's various divisions.

The Management of both Cimbix and MBG USA plans, as soon as time and
finances permit, to hire additional employees for its US based
operations especially in the areas of finance, sales, marketing and
investor/public relations.  To ensure that the most appropriate and
qualified employees are hired the Company anticipates either hiring
a qualified human resources person or outsourcing this responsibility
to a qualified third party who is qualified to aid in this selection
process.  Cimbix may also choose to outsource some of its marketing
roles by utilizing a series of independent contractors based on the
projected size of the market and the compensation necessary to
retain qualified employees.

ITEM 2.  DESCRIPTION OF PROPERTY

Cimbix's Head offices are located at #1710, 1000 Second Avenue,
Seattle, Washington, 98104. The Company's phone number is 206-973-
1895.

The Company also maintains a small sales and communications office in
Vancouver, B.C., Canada as well as a small marketing office in
Larkspur, California which is maintained by Mr. Donald Walker, the
Company's director and Vice President. The Canadian sales and
corporate communications offices are located at Suite 3400, 666
Burrard Street, Vancouver, British Columbia, Canada V5Z 4C2. The
telephone number is 604-647-3446 and the email address is
map@cimbix.com. The U.S. Marketing Offices are located at Suite 102,
702 College, Incline Village, Nevada 89450.  The telephone number is
415-479-1176 and the email address is mktg@cimbix.com.

Additionally, as MBG USA's Vice President of Investor Relations and
Business Development as well as the Company's Vice President of
Regulatory Affairs and Compliance officer and Corporate Secretary,
Mr. Robert Rosner maintains a small office on behalf of both the
Companies in the greater Los Angeles, California area. The U.S. sales
office and corporate compliance offices are located at Suite 134,
9663 Santa Monica Boulevard, Beverly Hills, California 90210.  The
toll free telephone number is 1-877-4CIMBIX (1-877-424-6249) and the
email address is compliance@cimbix.com.

ITEM 3.  LEGAL PROCEEDINGS

To the knowledge of the board of directors of Cimbix, the Company is
not currently party to any legal proceeding or litigation and none of
our property is the subject of a pending legal proceeding. We know of
no other threatened legal proceeding against the Company; however,
once the Company has successfully achieved a public listing of its
common securities, the Company anticipates beginning new legal
proceedings and litigation against several identified companies which
the Company believes are currently infringing on one or more of its
validly issued U.S. patents.  The U.S. District courts of Nevada have
already found the patents of the Company's wholly owned subsidiary to
be both valid and enforceable. MBG USA has already been awarded and
has received a cash settlement from one competitive entity who was
found guilty of past patent infringement.

ITEM 4.  SUBMISSION OF MATTER TO A VOTE OF SECURITY HOLDERS

No matters were submitted to the shareholders during the year ended
September 30, 2003.

PART II

ITEM 5.  MARKET FOR COMMON EQUITY AND RELATED SHAREHOLDER MATTERS

No established public trading market exists for Cimbix's securities.
The Company has no common equity subject to outstanding purchase
options. However, as a result of the share exchange with MBG USA,
the holders of 2,080,000 shares of MBG USA Common A shares received
2,080,000 shares of the Company's common stock (on a one for one
basis) and 500,000 (on a pro-rata basis) shares of the Company's
voting preferred stock. Every share of voting preferred stock has
twenty (20) votes compared to one vote for each share of Company
common stock. Each share of voting preferred is also convertible
into two (2) shares of common stock of the Company. Furthermore, the
holders of the 1,938,000 shares of MBG USA Common B Shares also
received 1,938,000 shares of the Company's common stock (one a one
for one basis) along with 1,938,000 warrants issued from the
Company's treasury (on a one for one basis).  Each warrant has an
exercise price of $0.05 per share. The warrants will be exercisable
one year after issuance, for a period of up to five years.

The Company is not aware of any of its common equity shareholdings
that could without a prior legal opinion from a U.S. securities
attorney which could be sold pursuant to Rule 144 under the
Securities Act or that the Company has agreed to register under the
Securities Act for sale by shareholders.

To date the Company has not paid any dividends on its common stock
and does not expect to declare or pay any dividends on its common
stock in the foreseeable future. Payment of any dividends will
depend upon the Company's future earnings, if any, its financial
condition, and other factors as deemed relevant by the Board of
Directors. There are 12,717,100 outstanding common shares as of
September 30, 2003 held amongst approximately 104 registered
stockholders of our common stock shareholders.

We have recently filed the required forms to be listed on the Over-
the-counters Bulletin Board with NASDAQ and pending approval from the
exchange.  A reserved ticker symbol "CMBX" has been reserved for the
Company.  There can be no assurances that the Company will be
approved by the exchange to start trading its common stock or that a
trading market will continue or that it will develop into an active,
liquid market for the Company's common stock.

ITEM 6.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

The following discussion of the financial condition and results of
operations of the Company should be read in conjunction with the
financial statements and the related notes thereto included elsewhere
in this annual report for the year ended September 30, 2003. This
annual report contains certain forward-looking statements and the
Company's future operating results could differ materially from those
discussed herein. Certain statements contained in this Report,
including, without limitation, statements containing the words
"believes," "anticipates," "expects" and the like, constitute
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of
the Company to be materially different from any future results,
performance or achievements expressed or implied by such forward-
looking statements. Given these uncertainties, readers are cautioned
not to place undue reliance on such forward-looking statements. The
Company disclaims any obligation to update any such factors or to
announce publicly the results of any revisions of the forward-looking
statements contained or incorporated by reference herein to reflect
future events or developments.

STATUS OF OPERATIONS

During the period up to September 30, 2003, the Company has engaged
in organizational activities, and the acquisition of the Millennium
Business Group USA, Inc.

For the current fiscal quarter, the Company anticipates incurring a
loss as a result of organizational expenses and expenses associated
with setting up a company structure to begin implementing its
business plan and the acquisition of MBG USA. The Company anticipates
that until these procedures are completed, it will not generate
revenues, and may continue to operate at a loss thereafter, depending
upon the performance of the business.

LIQUIDITY AND CAPITAL RESOURCES

The Company remains in the development stage and since inception, has
experienced no significant change in liquidity or capital resources
or shareholders' equity.  Since the execution of the share exchange
agreement with MBG USA a total of $21,300 have been private placed
into the Treasury of the Company in exchange for equity, (138,100
shares of common stock at $0.10 per share and an additional 50,000
shares of common stock at $0.15 per share).  These funds were used to
pay legal and accounting expenses along with several other miscellaneous
operational infrastructure costs.

The Company will need additional capital to carry out its business
plan. Although one of the Company's current directorsand officers, Mr.
Robert Rosner has, subsequent to September 30, 2003, privately placed
a total of $80,000 into the Company's MBG USA subsidiary in exchange
for equity in Cimbix, (120,000 shares of Cimbix common stock at $0.215
per share and 250,000 shares of Cimbix common stock at $0.20 per share)
the Company believes that in additional to its anticiapted cash flows
from operations it will need at least an additional minimum $250,000
in further private placement funding in order to fulfill its business
plan. Accordingly, there can be no assurance that any additional funds
will be available on terms acceptable to the Company or at all.

If we are able to raise the additional funding of $250,000 in private
placement transactions over the next twelve months to cover our
minimum cash requirements to persons who are "accredited investors",
it would be allocated as follows:

$200,000 to hire additional managers and staff in the sales,
         marketing and investor relations departments for our US
         offices.
$ 20,000 for outsourced advertising, graphic artwork and printing of
         marketing materials.
$ 30,000 for operational infrastructure costs including rent,
         communications, consumable supplies and travel.

In the process of carrying out its business plan, the Company may
determine that it cannot raise sufficient capital to support any of
its business divisions on acceptable terms, or at all. The Company's
board of directors has a fiduciary duty to act in the best interests
of the corporation and its shareholders. The board of directors may
decide that it is in the best interests of the corporation and its
shareholders to liquidate the business, enter into a new line of
business or engage in a business combination with another business.

The Company is not currently a party to any contracts, letters of
intent, commitments or agreements and is not currently engaged in
active negotiations with respect to any acquisitions other than
those which have been otherwise described on its current websites.
Although the Company does not presently intend to enter into a new
line of business or business combination, it reserves the right to
change its mind in an attempt to either complement or accentuate
its current business initiatives.  If the Company either raises
additional capital or engages in a business combination transaction
that implicitly increases the value of the Company, shareholders
may not personally recognize the increase in value. For example,
if the Company raises additional capital in the future at $0.03 per
share, even if there is a market for the Company's stock, it may not
support enough volume to permit a shareholder to liquidate shares at
a profit. Similarly, a business combination transaction could result
in any consideration being paid either to the Company or a
significant shareholder such as Dr. Andrew Willoughby, and minority
shareholders would simply continue to own shares in the resulting
business.

The Company's financial statements are presented on a going concern
basis which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business.  At September 30, 2003
we have been unsuccessful in our efforts to raise additional capital to
meet our plan of operations. Our cash position as of September 30, 2003
was $5,491. Since inception, we have recognized no significant revenue.
We have accumulated operating losses of $365,225 and as of September 20,
2003 we had a working a capital deficiency of $109,105.  At the present
time, and over the next twelve months, our primary focus will be to
develop our new initiatives and operational plan, to establish sales
and to explore various methods for raising additional funds.

We are presently in the development and promotional stages of our
business and we can provide no assurance that we will be successful
with our efforts to establish any revenue.  All required administrative
expenses are currently being paid by directors of the Company subject to
reimbursement. In order to pursue our existing operational plan, we are
dependent upon the continuing financial support of creditors and
stockholders until such time when we are successful in raising equity
capital to finance the operations and capital requirements of the
Company or until such time that we can generate our own revenue from
our various divisions.

RISK FACTORS

Dependence upon external financing

It is imperative that we raise additional capital to complete our
operational plan to promote and commercialize our newly acquired business
combinations and activities. We will also require funds to sustain our
business operations if we are not successful in earning revenues from our
various divisions. We estimate that we would require additional funding
of $250,000 to pursue our business strategy. If we are unable to obtain
equity financing upon terms that our management deems sufficiently
favorable, or at all, it would have a material adverse impact upon our
ability to expand our current operational plan. Any sale of share capital
will result in dilution to existing shareholders.

Dependence on key management

Our success is highly dependent upon the continued services of Dr. Andrew
Willoughby, our Chief Executive, Mr. Dickson Wong, our CFO, Mr. Doug
Johnson, our President  and Mr. Robert Rosner our VP Investor Relations
& Director of Regulatory Affairs.  If any of the foregoing persons were
to leave us, it could have a materially adverse effect upon our business
and operations.  We anticipate entering into employment contracts with
the foregoing individuals, but can provide no assurance that we will
come to terms for such employment agreements.

Dependence on Manufacturing Capabilities and Capacities

All of the various healthcare related products and services which the
Company represents on behalf of its various manufacturers, are fully
functional devices manufactured to commercial specifications and which
currently have all the necessary pre-market regulatory approvals in place.
However, there can be no assurances that the same standard and level of
Quality Assurance and Quality Control will still be employed by these
same manufacturers with increased levels of mass commercial production
for these same devices and products.  The in-ability to meet or exceed
minimum performance production standards could adversely impact the
functionality of one or more of the devices marketed and sold by the
company which in turn could negatively impact existing vendor
relationships and potentially the continued viability of our business.
Furthermore, given heightened demand for the company's products and
limited manufacturing capabilities, the company's manufacturers may not
be able to meet the required manufacturing capacities for the products
marketed and sold by the Company, which in turn could cause a shortage
in supply. If we are unsuccessful in addressing these risks, or finding
a suitable alternate supply of a similar or like product our business
could potentially fail.

Intellectual Property Strategy

With the four US Patents that are currently owned by the Company's wholly
owned  subsidiary, MBG USA has already been able to execute a U.S. court
directed legal settlement with one infringing company.  On June 26, 2002,
this resulted in a fully paid up license fee and cash settlement for MBG
USA of $280,000.

It is the Company's intention over the next several months, to develop and
implement a legal defense strategy to help extract financial compensation
from certain other entities which have also chosen to willfully infringe
on the Company's Patents by commercializing similar technologies.  The
Company's ability to pursue these opportunities is in large part contingent
upon our obtaining additional capital to assist in the associated legal and
operational infrastructure costs. If the company is unable to raise such
additional funds it is possible that the company business could potentially
fail.  Furthermore, even though the company's patents have been upheld as
valid and enforceable by a US Nevada District Court Judge, there can be no
assurances that subsequent legal proceedings will result in similar awards
and or financial settlements with other potential defendants.

Market Analysis

Management's market analysis has determined that there is a significant
market for our products within certain niche markets of the healthcare
industry and related internet communications industry.  These markets are
defined by a specific customer demographic. As a result of which, the
company has utilized various resources in developing and producing
marketing and promotional materials which are focused on these market
sectors and customers.  If the Company's market analysis proves to be in
-correct or inaccurate, this could have a negative impact on the Company's
ability to successfully commercialize its various products and achieving
its anticipated rates of initial market penetration. In turn this could
affect the Company's ability to generate anticipated gross sales revenues
and ultimately profitability. If we are unsuccessful in addressing these
risks, our business will most likely fail.

We are in our early stages of development and face a risk of business
failure.

We are in our early stages of development and have just engaged a few
companies to market, sell and distribute our products. We have no way
to evaluate the likelihood that we will be able to operate the business
successfully.  The likelihood of success must be considered in light of
the problems, expenses, difficulties, complications and delays encountered
in connection with the technology industry. We recognize that if we are
unable to generate significant revenues from our various divisions, we
will not be able to earn profits or continue operations. There is only a
limited history upon which to base any assumption as to the likelihood
that we will prove successful, and we can provide investors with no
assurance that we will generate any additional operating revenues or ever
achieve profitable operations from our current business initiatives . If
we are unsuccessful in addressing these risks, our business will most
likely fail.

We may not be able to sell our products.

In the event that our products are successful, we may be unable to sell
our products.  There can be no assurance that we will be able to sell
our products at all, or enough at prices to maintain operations.

We may suffer product liability from manufacturing defects

In the event that our products are successful, we may suffer substantial
product liability from mass manufacturing due to defects.  We do not
currently maintain insurance for our products and product liability
resulting from manufacturing defects. Our manufacturers have however
agreed to replace all defective products at their expense.

If there is a market for our common stock, our stock price may be
volatile

If there's a market for our common stock, we anticipate that the market
price of our common stock will be subject to wide fluctuations in
response to several factors, including:

1)   actual or anticipated variations in our results of operations;
2)   our ability or inability to generate new revenues;
3)   increased competition; and
4)   conditions and trends in the technology industry.


ITEM 7.  FINANCIAL STATEMENTS

Our financial statements are stated in United States dollars and are prepared
in accordance with the United States generally accepted accounting principles.
The audited financials statements ended September 30, 2003, the independent
auditor's report, and the notes to the financial statements are attached as
Exhibit 13 with this filing.


Index  to  Financial  Statements:

1.     Independent  Auditors'  Report;

2.     Audited  Consolidated  Financial  Statements

     a.   Consolidated Balance Sheets as at September 30, 2003 and 2002;

     b.   Consolidated Statements of Changes in Capital Deficit for the
          period from August 17, 2000 (inception) to September 30, 2003;

     c.   Consolidated Statements of Operations for the years ended
          September 30, 2003 and 2002 and for the cumulative period from
          August 17, 2000 (inception) to  September 30, 2003;

     d.   Statements of Cash Flows for the years ended September 30, 2003 and
          2002 and for the cumulative period from August 17, 2000 (inception)
          to  September 30, 2003;

     e.   Summary  of  Significant  Accounting  Policies

     f.   Notes  to  Financial  Statements.

ITEM 8.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
         AND FINANCIAL DISCLOSURE

None

ITEM 8A.  CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures. Our chief
executive officer and our principal financial officer, after
evaluating the effectiveness of the Company's "disclosure controls
and procedures" (as defined in the Securities Exchange Act of 1934
Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by
this quarterly report (the "Evaluation Date"), has concluded that as
of the Evaluation Date, our disclosure controls and procedures were
adequate and designed to ensure that material information relating to
us and our consolidated subsidiaries would be made known to him by
others within those entities.

(b) Changes in internal control over financial reporting. There were
no significant changes in our internal control over financial
reporting during our most recent fiscal quarter that materially
affected, or is reasonably likely to materially affect, our internal
control over financial reporting.

PART III

ITEM 9.  DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL
         PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT

Board of Director Members:

As of September 30, 2003 the Company had the following three (3) board of
Director members.

Dr. Andrew Willoughby - Chairman
Mr. Robert Rosner -Director
Mr. Donald G. Walker - Director

On October 31, 2003 Mr. Douglas P Johnson joined the Company's Board of
Directors which now comprised four (4) board members in total.

The following table sets forth the name, age and position of each
director and executive officer of Cimbix as at January 13, 2004:

<TABLE>
<CAPTION>
Name                    Age  Position
--------------------------------------------------------------------

                      <c>  <c>
Dr. Andrew JM Willoughby  42   Chief Executive Officer, Director
Douglas P Johnson (i)     63   President, Director & Vice President of
			       Vitacore Consumer Products Division
Dickson Wong              38   Chief Financial Officer
Robert Rosner             39   Vice President of Regulatory Affairs and
                               Compliance, Corporate Secretary and Director
Donald G Walker           56   Vice President of Sales and Licensing, Director
Marlon Shangi             43   Chief Technology Officer
David Roberts             56   Director of Corporate Communications
David Willoughby          41   Vice President of Sales, Americas and Europe
Dr. David Chuah           51   Vice President of Research and Development

</table>

Effective March 24, 2003, Dr. Andrew Willoughby and Donald Walker
were elected directors of the Company and pursuant to the share
exchange agreement with MBG USA, joined Mr. Edwin Lao as board
members.  The board of directors of the Company was thus expanded to
three members.  On August 12, 2003, Mr. Robert Rosner was elected to
the Company's board of directors.  Subsequent to Mr. Lao's retirement
in August 2003, Mr. Douglas Johnson joined the Company's board of
directors October 31, 2003 now totaling four (4) members.

Set forth below is a brief description of the background and business
experience of each of our executive officers and directors for the
past five years.

Dr. Andrew J.M. Willoughby, DMD, NDEB (Certificant)- Chairman  and
C.E.O.   Dr. Willoughby will assume responsibility for the day-to-
day operations of The Company and for establishing and maintaining
positive cash flows from operations.  Concurrent with this position
Dr. Willoughby holds several other Sr. Management positions with a
number of healthcare related companies where over the years he has
primarily been responsible for establishing new sales, marketing and
distribution programs within the Canadian healthcare market for a
variety of unique products, technologies and companies. Dr.
Willoughby has extensive experience in the manufacturing, sales and
distribution of healthcare products and in the licensing and
technology transfer of healthcare related IP (Intellectual
Property).  Concurrent with this position, Dr. Willoughby serves as
President and COO of a publicly reporting, trading issuer named
Claremont Technologies Corp ["Claremont" NASD OTCBB ticker symbol
"CTTG"] - whose primary focus is in the wireless communications
business. Willoughby currently holds four (4) US patents pertaining
to osseointegrated dental implant componentry.  In June 2002 [with
the help of the US law firm Niro, Scavone, Haller and Niro], Dr.
Willoughby's company - The Millennium Business Group USA, Inc., won
an out-of-court settlement (Nevada US Superior Court) for Patent
Infringement [relating to his patents] from a Swiss based
multinational dental implant company.  Dr. Willoughby has a strong,
proven track record of managing and building start up companies into
successful, commercially viable businesses and will bring to bear
for the benefit of the Company, his expertise in the areas of IP
Transfer, Licensing and in managing and training distributor sales
forces in various industrial and retail channel markets.
Previously, Willoughby was a practicing dentist in Manitoba, Canada
where for six (6) and a half years (until 1993) his main focus was
general restorative and osseointegrated implant dentistry.

Dickson D. Wong, CA., TEP., Chief Financial Officer. - Mr. Wong
currently serves as the Company's Chief Financial Officer,
responsible for implementing and maintaining the necessary
accounting and financial systems for the day-to-day operations of
the Company.  Dickson also plays a key role in evaluation of
potential mergers and acquisitions and any secondary financings for
the Company. As the Company's CFO, Mr. Wong reports directly to the
Company's C.E.O., Dr. Andrew Willoughby.  Mr. Wong has been
directly involved in developing the Company's various Financial
Accounting systems and its Pro-Forma financial models as well as the
necessary cash flow models and financial projections with respects
to how the "Use of Proceeds" shall be managed as Cimbix begins to
implement its  various business initiatives and financial models.
Mr. Wong has experience in providing professional advice to real
estate developers and contractors, family estates and trusts,
service based industries in the hospitality, health care and
technology sectors and taxpayers requiring assistance in resolving
disputes with Canada Customs and Revenue Agency and cross border
taxation issues.  Mr. Wong is a senior partner with Adams & Wong - a
full service Canadian Chartered Accountancy firm located in
Vancouver, British Columbia. The primary focus of Adams & Wong
centers around Canadian and international tax advice and there
extensive knowledge of the intricacies of the Canadian Tax
Legislation is complemented by their auditing, general accounting
and tax compliance services group.  Mr. Wong is also a member of the
Society of Trust and Estate Practitioners, Canadian Tax Foundation
and the Hong Kong Canada Business Association, Vancouver Chapter. He
was the past Treasurer of the University of British Columbia Alumni
Association and acted as Speaker on Canadian tax at the British
Columbia Business Immigration Program.

Mr. Donald G. Walker B.Com, LLB, M.B.A., - Vice President of Sales
and Licensing, General Corporate Council & Director.  Walker is an
active member of the California Bar and has been a lawyer in private
practice for over 25 years as both a partner and sole
practitioner, representing clients in such diverse areas as general
corporate law, personal and corporate tax planning, real estate,
immigration, insurance coverage litigation and general litigation.
Walker has acted for numerous corporate executives of public
companies in respect to various issues of fiduciary and ethical
duties.  Between 1975 and 1981 Walker was responsible
for incorporating well over four hundred (400) new privately held
companies, as well as designing and implementing their various
capital share structures and requirements for corporate governance.
As an entrepreneur, Walker also has considerable experience with
successfully developing and managing numerous privately held start-
up enterprises including the development of numerous real estate
projects in both Canada and the U.S., recently completing the
development of the Mexican Consulate in San Jose, Ca.  Currently,
Walker is an owner of a private telemarketing company based in San
Diego, California which operates a 135 employee call-center which
markets self improvement courses and other products for various
clients who contract for the services of this call-center.  As the
founder of D.G. Walker & Associates, Attorney's-at-Law, Walker also
currently represents numerous Canadian and Chinese investors as part
of a specialized immigration practice.  Walker received both his
B.Com and LLB from the University of Alberta, Canada and his M.B.A.
from the University of California.  As a member of the Company's
Board of Directors as well as its general corporate counsel Walker
brings to bear proven legal expertise, an extensive familiarity with
US corporate governance issues, as well as a strong working
knowledge of how to integrate and manage the corporate sales
function with various potential licensing strategies.

Mr. Douglas Johnson - President, Director & Vice President of
Vitacore Consumer Products Division. For the past thirty years,
Johnson has provided strategic sales and marketing services to a
variety of industry sectors and has extensive management experience
in building and running worldwide distribution based sales
departments. Specifically, Johnson has a proven history of being
able to successfully train and motivate field sales personnel to
help grow their sales skills and related productivity. Johnson has
also developed an extensive network of industry contacts and business
relationships with a diverse array of global healthcare
manufacturers and distribution channels. As a result, Johnson has
acquired an extensive working knowledge of how to best maximize the
integral relationship between manufacturers and distributors.
Johnson has used this expertise to develop and implement many highly
successful 'manufacturer assisted' sales and service support
programs which have played a key role in helping to 'drive' both
substantially increased product sales and market share for
manufacturers and distributors alike. Previously, Johnson worked in
the sales department of Marion Pharmaceutical Labs, where he was an
award winning salesman and district manager. After being promoted to
National Sales Manager for the Marion Scientific division, and then
to Vice President of National Sales, Marion Scientifics' annual
sales grew from $4 Million to $40 Million USD under Johnson's
leadership. Johnson was then hired as the Vice President of Sales by
a national laboratory supply house named Curtis Matheson Scientific
where he was directly responsible for overseeing a 400+ person sales
force sales who were collectively generating sales in excess of $400
Million annually. As President of Cimbix's Consumer Products
Division, Johnson will be responsible for the day-to-day operations
of Vitacore and for managing the on-going business relationship with
its NITA HealthWEB client. Johnson's experience and strong working
knowledge of the North American healthcare distribution network,
nutraceutical and pharmaceutical drug industries will be of
invaluable assistance in helping to successfully implement
Vitacore's various initiatives.

Mr. Robert Rosner - Vice President Regulatory Affairs & Compliance:
Mr. Rosner serves as the Company's Vice President of Regulatory
Affairs and Compliance, Corporate Secretary and as a member of
Cimbix's board of directors.   Mr. Rosner was appointed to the
Company's board of directors and as Vice President of Regulatory
Affairs and Compliance and Corporate Secretary on August 15, 2003.
For the past two years Mr. Rosner has also functioned as a VP of
Investor Relations and Business Development for MBG USA.  From
September 1999 till September 2003, Rosner was also the President of
First Cypress Technologies Inc., a junior mining company listed on
the NASDAQ-OTC Bulletin Board.  He has been the owner and the
president of Rosner Communications Inc. since July 1985.  Rosner
Communications Inc. provides consulting services to public
companies.  Mr. Rosner has been the president and a director of
Moreno Ventures Inc., a company listed on the Canadian Venture
Exchange, since July 1994.  Mr. Rosner has been the president and a
director of Fortuna Ventures Inc., a company listed on the Canadian
Venture Exchange, since June 1996.  Mr. Rosner has been the
president and a director of Superior Networks, Inc., a company
listed on the NASDAQ-OTC Bulletin Board, since February 2002. Mr.
Rosner was  a director of Global Tree Technologies, Inc., a company
currently listed on the Canadian Venture Exchange, from May 1993 to
February 1998.  Moreno Ventures, Inc. and Fortuna Ventures, Inc. are
both companies engaged in the business of mineral exploration.
Global Tree Technologies, Inc. is a company engaged in the business
of marketing of a fast growing tree for production of wood products.
Mr. Rosner has been a member of the Independent Order of Foresters
since 1989, and a member of its executive committee in 1994.  As MBG
USA's VP Investor Relations and Business Development Mr. Rosner
currently works and operates out of the Company's California
offices.

Mr. Marlon A. Shangi -  Chief Technology Officer. Mr. Marlon Shangi
functions as the Company's Chief Technology Officer. In this
capacity, Shangi will be actively involved in establishing strategic
alliances for the Company's new wireless Consultancy Services
division system and will oversee all  related sales and marketing
initiatives. Shangi will also be directly responsible for the
commercialization of the Company's various Wi-Fi technologies and
products. Mr. Shangi has over 15 years in the telecommunications
industry Mr. Shangi is an experienced, manager, network systems
designer and an industry analyst/consultant who has successfully
brought many related new wireless technologies to market.  Mr.
Shangi has worked at Ericsson Communication Canada, AT&T Canada,
and Sprint Canada. He has been a manager involved in the planning,
designing, and deploying of large scale wireless and landline
telecommunications networks. While at Ericsson Canada Mr. Shangi was
responsible for the team that designed and installed the Rogers AT&T
National wireless Data network.

Mr. David Willoughby - Vice President of Sales Americas and Europe.
For the past twenty years, David Willoughby has built a career as a
marketing and sales manager, working closely with Canadian, US, and
international channel sales and marketing teams to develop
outstanding channel sales and marketing programs across dental,
biotechnology, industrial and the information technology service
sectors. In this capacity, David Willoughby has been responsible for
building and managing existing primary distribution channels to
facilitate joint marketing, regulatory approval processes, partner
communication, product marketing push/pull strategies(within partner
channels) and channel marketing budget forecasts; management of
collateral inventory and fulfillment pertaining to channel partners,
joint activities, 'in- house' sales representatives and sales agency
groups; development of regional marketing strategies aimed at,
growing product line sales, line appeal and new product
introductions with overall revenue enhancement objectives;
application of SWOT and environmental scanning and analysis
procedures to assure consistency with overall corporate business
goals and marketing strategies, as well as, financial ROI, brand
synergy, potential impact and visibility and execution requirements;
emphasis on client relationships through commissioning and
coordinating channel marketing research of both channel partner and
existing 'end-user' customer base; and the creation and high
visibility techniques of product line content for collateral
exposure and secondary support of all promotion runs including
media, seminars, and tradeshows.  Mr. Willoughby will function as
Vitacore's European and International Sales Manager and will be
responsible for effectively executing sales and marketing
strategies, building and retaining excellent customer service
relationships; promoting positive consultative client relationships
and developing new business partnerships for the Company.

Dr. David Chuah - Vice President of Research and Development,
Vitacore division. Dr. Chuah serves as Vitacore's Vice President of
Research and Development and is responsible for the selection and
development of all of Vitacore's various vitamin, mineral and herbal
supplements. Since graduating from England's prestigious London
University, with a Ph.D {Doctorate} in Bio-Chemistry, David K. Chuah
has been convinced that the vast majority of cancer and disease
causing processes are largely attributable to various forms of
bacterial infections. For the better part of his career as a
molecular bio-chemist, Dr. Chuah has also conducted private research
into how electro-magnetic and low range radio frequencies play an
important part in healing disease processes at the molecular and sub
molecular levels. As Dr. Chuah's understanding of how various
disease processes affect the human body on a cellular level have
grown and his research into alternative medicine practices matured,
Dr. Chuah began to see an opportunity for combine his knowledge of
Chinese herbal medicines [teas] with the protocols he had previously
developed in radio frequencies. It was at this point in his career
that Dr. Chuah began helping seriously ill people manage their
diseases use his unique form of alternative medicine to help treat
seriously ill and in many instances, terminally ill patients [by
western medical standards]. Dr. Chuah's protocols helped save the
lives of many cancer patients but even though he admittedly, still
had his 'failures' he found that in the majority of cases his
alternative approaches were at the very least, able to dramatically
increase his patients quality of life.

For almost twenty five years now, Dr. Chuah has continued his
private research and has been actively working as a health
consultant and master Chinese herbalist. Utilizing a unique blend of
Traditional Chinese medicines, Dr. Chuah has been able to isolate
and extract concentrated tinctures of these age old, proven herbal
medicines and successfully combine these proprietary formulations
with wild native medicines - the combination of which he has used to
help assist terminal sickness and incurable diseases with very good
results.  David Chuah is currently working with several Aboriginal
groups in an attempt to develop a Native Medicine Clinic and Medical
school which incorporates traditional Native Medicine that can be
successfully blended with Chinese Herbal practices and essences of
other medicines from different cultures. Dr. Chuah believes that the
future of medicines lies in the complex world of nutraceuticals and
phytotonics {"botanicals} rather than in manufacture and propagation
of synthetic molecules. Amongst certain Aboriginal communities,
David Chuah is known as "Ashanti", a spiritual name meaning the
joining of the mountain and the earth.

TERM OF OFFICE

Our  officers are  appointed for a one-year term to hold office
until the next annual  general  meeting  of  our  shareholders  or
until removed from office in accordance  with  our  bylaws.  Our
officers  are  appointed  by  our  board of directors  and  hold
office  until  removed  by  the  board.

SECTION  16(a)  BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Not Applicable as we are not a publicly traded company.

ITEM 10. EXECUTIVE OFFICERS COMPENSATION

The table below summarizes all compensation awarded to, earned by,
or paid to our executive officers by any person for all services
rendered in all capacities to us for the fiscal year ended September
30, 2003.  No officers or directors received annual compensation in
excess of $100,000 during the last two complete fiscal years.

                     Fiscal Year 2003 Officers Annual Compensation Table
<table>
<caption>
                           Annual  Compensation         Long  Term  Compensation
                           --------------------         ------------------------
                                                Other                                   All
                                                Annual                                  Other
                                                Compen  Restricted                      Com-
                                                sation  Stock    Options/  LTIP         pen-
Name            Title     Year  Salary   Bonus  (stock) Awarded  SARs (#)  payouts ($)  sation
------------  ----------  ----  -------  -----  ------  -------  --------  -----------  ------
<S>          <C>          <C>  <C>        <C>    <C>     <C>      <C>       <C>          <C>

Dr. Andrew   Chairman (1) 2003   $0        0       0      0         0        0            0
Willoughby   Director

Edwin Lao    Former   (2) 2003   $0        0       0      0         0        0            0
	     President
	     & Director

Dickson      CFO          2003   $0        0       0      0         0        0            0
Wong

Marlon       Chief        2003   $0        0       0      0         0        0            0
Shangi       Technology
             Officer

Donald       VP Sales     2003   $0        0       0      0         0        0            0
Walker       & Licensing
             Director

Robert       Corporate    2003   $0        0       0      0         0        0            0
Rosner       Secretary,
             VP Reg.
             Affairs,
       	     Director

David        Director of  2003   $0         0      0      0         0        0            0
Roberts      Corporate
             Communic.

David        VP Int'l     2003   $0         0      0      0         0        0            0
Willoughby   Sales
             Vitacore

Dr. David    VP of        2003   $0         0      0       0         0       0            0
Chuah        R & D
             Vitacore

</table>

(1) During the fiscal yearended September 30, 2003, Dr. Andrew
Willoughby received $4,000 in cash remuneration from Cimbix.

(2) Mr. Edwin Lao retired as the Company's President and Director
in August, 2003 and he was not replaced by Mr. Doug Johnson until
Oct 31, 2003.

Note: None of the officers or directors received any form salary
as shown, except as noted on (1) due to the financial constraints
of the company.

On September 3, 2003 the Company's Board of Directors developed
and adopted a Board resolution [effective October 1, 2003] which
outlined an annual compensation plan for both its executive
officers [and that of MBG USA, its wholly owned subsidiary] for
the upcoming fiscal year ending Spetember 30, 2004. This plan had
two basic componenets as outline in the table below;

i) an annual salary for fiscal year 2004 which is to be paid over
time, based on available cash flow from the company's various
operating divisions. Any deficits or shortfalls in these actual
amounts paid to the individual officers throughout fiscal year 2004
shall be accrued [in their favor] on the company's balance sheet;
and

ii) an equity compensation plan for each of the Company's individual
senior managers and officers as part of an their 2004 annual
compensation package [implementable at any point after March 31,
2004 so long as these same individuals are still employed by the
Company at this time and are performing their job responsibilities
in a professional manner] which authorizes the issuance of the
following amounts of the Company's common shares:


<table>
<caption>
  Fiscal Year 2004 Officers and Senior Managers Annual Salary & Equity Compensation Table
                           Annual  Compensation         Long  Term  Compensation
                           --------------------         ------------------------
                                                Other                                   All
                                                Annual                                  Other
                                                Compen  Restricted                      Com-
                                                sation  Stock    Options/  LTIP         pen-
Name            Title     Year  Salary   Bonus  (stock) Awarded  SARs (#)  payouts ($)  sation
------------  ----------  ----  -------  -----  ------  -------  --------  -----------  ------
<S>          <C>          <C>  <C>        <C>  <C>       <C>      <C>      <C>          <C>

Dr. Andrew   Chairman     2004  $100,000   0    300,000     0        0        0            0
Willoughby   Director


Doug         President    2004  $ 60,000   0    200,000     0        0        0            0
Johnson      Director


Dickson      CFO          2004  $      0   0    200,000     0        0        0            0
Wong

Marlon       Chief        2004  $      0   0    100,000     0        0        0            0
Shangi       Technology
             Officer

Donald       VP Sales     2004  $      0   0    175,000     0        0        0            0
Walker       & Licensing
             Director.

Robert       Corporate    2004  $ 45,000   0     50,000      0        0        0            0
Rosner       Secretary,
             VP Regul.
             Affairs,
	     Director.

David        Director of  2004  $      0   0     50,000      0         0       0            0
Roberts      Corporate
             Communic.

David        VP Int'l     2004  $      0   0     50,000      0         0       0            0
Willoughby   Sales
             Vitacore

Dr. David    VP of        2004  $      0   0     50,000      0         0       0            0
Chuah        R & D
             Vitacore

Maribel      Office       2004  $      0   0     45,000      0         0       0            0
Jordan       Admin.

</table>

Note: Any deficits or shortfalls in the actual salary amounts
paid to the above individual officers shall be accrued [in
their favor] on the company's balance sheet.

As of January 13, 2004, none of the above authorized allotment
of the Company's common stock has been issued to its officers
or directors.

The following is the authorized allotment of the Company's
common stock to its officers and senior managers:
<table>
<caption>
                                                       Number of Shares
                                                      -----------------

                                                      <c>
Andrew J.M. Willoughby - Chairman & C.E.O.                  300,000
Dickson D. Wong - C.F.O.                                    200,000
Douglas P.Johnson - President, Director                     200,000
Donald G. Walker - VP Channel Market & Licensing            175,000
Marlon A. Shangi - Chief Technology Officer                 100,000
Dr. David Chuah -  VP R&D - Vitacore div.                    50,000
Robert W. Rosner - VP Regulatory Affairs                     50,000
David G. Roberts - Director of Corporate Communications      50,000
David J. Willoughby - VP Sales - Americas & Europe           50,000
Maribel Jordan - Office Administrator                        45,000
                                                           --------
                                                          1,245,000
</table>

As of September 30, 2003, none of the executive officers had any
sort of binding employment contracts with the Company.  However,
in addition to being a Vice President of Regulatory Affairs for
the Company, Mr. Robert Rosner was promised [for the 2004 fiscal
year] an annual base salary of $60,000 as Vice President of Investor
Relations and Business Development for the Company's wholly owned
subsidiary, MBG USA. In this capacity Mr. Rosner is responsible
for managing the expansion of MBG USA's US sales, marketing and
investor relations offices in Los Angeles, California.

Additionally, Dr. Andrew Willoughby was promised [for the 2004 fiscal
year]an annual base salary of US$60,000 as President of the Company's
wholly owned subsidiary, MBG USA. In this capacity Dr. Willoughby is
responsible for overseeing the day-to-day operations of MBG USA and
developing and implementing it's proposed patent infringement law
suit case(s).

A portion of any employee compensation likely would include the right
to acquire stock in the Company, which would dilute the ownership
interest of holders of existing shares of its common stock.

DIRECTOR'S COMPENSATION:

In August, 2003 Mr Edwin Lao retired as President and Director of
the Company which left the Company with three (3) remaining Board of
director members as listed in the table below. Although the directors
of the Company do not currently receive any cash compensation for
their services, on September 3, 2003 the Company's Board of Directors
did unanimously adopt a board resolution authorizing the issuance
[for the upcoming fiscal year 2004 ending Septemeber 30, 2004] the
following number of the Company's common shares to each of the
following three Board of Director members as part of their annual
Director's compensation package.  As of January 13, 2004, the shares
to the Company's directors had not been issued.

<table>
<caption>
                         Directors shares
                                                      Nos. of Common
                                                 shares to be issued
                                                        ------------

                                                       <c>
Dr.Andrew Willoughby - director                          75,000
Mr Donald Walker  - director                             75,000
Mr.Robert Rosner - director                              75,000
                                                         --------
                                                         225,000
</table>

(i) At the time of the Board's resolution, Mr. Doug Johnson was not an
authorized/appointed board member, however, the Board did authorize
the issuance to Mr. Johnson a total of 75,000 common shares upon his
official appointment to the Company's board of directors.

As of September 30, 2003 the Company has not adopt any compensation
committee or compensation policies. See "Certain Relationships and
Related Transactions." Other than as detailed above, the Company has
no stock option,retirement, incentive, defined benefit, actuarial,
pension or profit-sharing programs for the benefit of directors,
officers or other employees, but the Board of Directors may recommend
adoption of one or more such programs in the future.

ITEM 11. SECURTIY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
         MANAGEMENT

The following table sets forth, as of September 30, 2003, Cimbix's
outstanding common stock owned of record or beneficially by each
executive officer and director and by each person who owned of
record, or was known by Cimbix to own beneficially, more than 5% of
its common stock, and the shareholdings of all Executive Officers and
Directors as a group. Each person has sole voting and investment
power with respect to the shares shown.

As of September 30, 2003 the total number of issued and outstanding
common shares in the Company was 12,717,100.  5% of which equals
635,855 shares.

<TABLE>
<CAPTION>
                                                       Amount of         Percent
                           Name and address            beneficial        of
Title of Class             of beneficial owner         ownership         class
                           -----------------------------------------------------
<S>                        <C>                         <C>               <C>
Common Stock                Dr. Andrew Willoughby          1,175,000*      9.24%
                            Chairman, CEO
                            #123, 8415 Granville Street
                            Vancouver, BC Canada

Common Stock                Dickson Wong                      30,000**      0.0236%
                            CFO
                            #620, 650 West 41st Ave
                            Vancouver, BC Canada

Common Stock                Donald Walker                     75,000***     0.0589%
                            Director, VP of Channel
                            Marketing & Licensing
                            #102, 702 College
                            Incline Village, Nevada USA


                                                         -------------    -------
                                                            1,280,000      10.06%
</table>

Total combined share position of all executive officers
and directors as a group consists of 3 persons

Note:
* Andrew Willoughby additionally holds 282,500 20:1 Super voting
Preferred B shares each of which are convertible into two (2)
common shares.
** Dickson Wong additionally holds 7,000 20:1 Super voting
Preferred B shares each of which are convertible into two (2)
common shares.
***Donald Walker additionally holds 18,000 20:1 Super voting
Preferred B shares each of which are convertible into two (2)
common shares.

Under the rules of the Securities and Exchange Commission, a person
(or group of persons) is deemed to be a "beneficial owner" of a
security if he or she, directly or indirectly, has or shares the
power to vote or to direct the voting of such security, or the power
to dispose of or to direct the disposition of such security.
Accordingly, more than one person may be deemed to be a beneficial
owner of the same security.  A person is also deemed to be a
beneficial owner of any security, which that person has the right to
acquire within 60 days, such as options or warrants to purchase the
common stock of Cimbix.  There were no rights outstanding as of
January 13, 2004 entitling owners to acquire our common stock within
60 days.

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

No director, executive officer or nominee for election as a director
of the Company and no owner of five percent or more of Cimbix's
outstanding shares or any member of their immediate family has
entered into or proposed any transaction in which the amount involved
exceeds $60,000 except as noted above.

ITEM 13.  EXHIBITS AND REPORTS ON FORM 8-K

(a)     Exhibits  and  Index  of  Exhibits

<table>
  Exhibit
  Number                         Description of Exhibit
--------------     -------------------------------------------------

                <c>
  3.2                Amendment of Articles of Incorporation (1)
 10.1                Share Exchange Agreement between the Company and
                     the Millenium Business Group USA, Inc. (2)
 13.1                Audited Consolidated Financials Statements for
                     the year ended September 30, 2003 (3)
 16.1                Change of Certifying Accountant (4)
 31.1                Certification 302, CEO (3)
 31.2                Certification 302, CFO (3)
 32.1                Certification 906, CEO (3)
 32.2                Certification 906, CFO (3)
 --------------     -------------------------------------------------
</table>
(1)     Previously  filed  with  the  Securities  and  Exchange
Commission as an exhibit  to  the  Form 8-K dated  August 26, 2003.
(2)     Previously  filed  with  the  Securities  and  Exchange
Commission as an exhibit to  the  Form 8-K dated April 9, 2003 and
August 19, 2003.
(3)     Attached as exhibit to the current Form 10-KSB
(4)     Previously  filed  with  the  Securities  and  Exchange
Commission as an exhibit to  the  Form 8-K dated July 2, 2003.


(b)     Reports  on  Form  8-K.

On July 2, 2003, we reported with the US Securities and Exchange
Commission the dismissal of Manning Elliott, Chartered Accountants
and the appointment of Morgan & Company, Chartered Accountants as our
principal independent accountant.

On April 9 and August 19, 2003, we reported with the US Securities
and  Exchange Commission that we had entered into a Share Exchange
Agreement between the shareholders of the Millenium Business Group
USA, Inc. and the Company.  The subsequent filing reported the
audited financial information of the Millenium Business Group USA,
Inc., a wholly owned subsidiary.  The Millenium Business Group USA,
Inc. provided an audited financials as well as a proforma unaudited
financials as of September 30, 2002, as if the transaction was
completed and all obligations had been assumed as of September 30,
2002.

On August 26, 2003,  we  reported with the US Securities and
Exchange Commission that we had changed the Company's name from
Corporate Development and Innovation, Inc. to Cimbix Corporation.

On November 26, 2003, we reported with the US Securities and Exchange
Commission that we appointed a new President and director, Mr.
Douglas P Johnson.

ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

AUDIT FEES

The aggregate fees billed for each of the fiscal years ended
September 30, 2003 and 2002 for professional services rendered by the
principal accountant for the audit of Cimbix's annual financial
statements and review of the financial statements included in the
registrant's Form 10-QSB or services that are normally provided by
the accountant in connection with statutory and regulatory filings or
engagements for those fiscal years were estimated at $6,800 and
$4,000 respectively.

AUDIT RELATED FEES

None

TAX FEES

None

ALL OTHER FEES

None


<PAGE>
                                   SIGNATURES



In  accordance  with  Section  13  or  15(d) of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


CIMBIX CORPORATION


By:  /s/  ANDREW JM WILLOUGHBY
     ___________________________________
     ANDREW JM WILLOUGHBY, Chief Executive Officer and Director
     Date:     January 27, 2004


In accordance with the Securities Exchange Act of 1934, this report
has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.


By:  /s/ ANDREW JM WILLOUGHBY
     ___________________________________
     ANDREW JM WILLOUGHBY, Principal Executive Officer
     Chief Executive Officer and Director
     Date:     January 27, 2004


By:  /s/  DICKSON WONG
     __________________________________
    DICKSON WONG, Principal Accounting Officer,
    Chief Financial Officer
    Date:     January 27, 2004




<PAGE>